Plus Therapeutics Inc. (PSTV)
0.72
-0.07 (-8.52%)
At close: Apr 11, 2025, 1:20 PM
-8.52% (1D)
| Bid | 0.72 |
| Market Cap | 12.31M |
| Revenue (ttm) | 2.96M |
| Net Income (ttm) | -12.98M |
| EPS (ttm) | -2.34 |
| PE Ratio (ttm) | -0.31 |
| Forward PE | -0.57 |
| Analyst | Buy |
| Ask | 0.74 |
| Volume | 246,621 |
| Avg. Volume (20D) | 15,890,827 |
| Open | 0.78 |
| Previous Close | 0.79 |
| Day's Range | 0.72 - 0.76 |
| 52-Week Range | 0.24 - 2.67 |
| Beta | 0.67 |
About PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to d...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 11, 2001
Employees 20
Stock Exchange NASDAQ
Ticker Symbol PSTV
Website https://www.plustherapeutics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 1142.92% from the latest price.
Stock ForecastsNext Earnings Release
Plus Therapeutics Inc. is scheduled to release its earnings on May 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-23.68%
Plus Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
3 weeks ago
+170.06%
Plus Therapeutics shares are trading higher after the company announced that the FDA accepted the name REYOBIQ for Co.'s lead asset.
